Article

Diana Davis Spencer Foundation pledges $5 million to Foundation Fighting Blindness for inherited retinal disease research

Organization makes a commitment to expand translational research acceleration program and fund career development award.

The Foundation Fighting Blindness has announced the launch of the Diana Davis Spencer Foundation Enhanced Translational Research Acceleration Program, designed to accelerate the progress of particularly promising preclinical research toward an Investigational New Drug filing that can lead to follow-on investment and clinical trials — providing a robust and diverse pipeline of potential therapies to fight inherited retinal degenerative diseases.

"We are honored by the Diana Davis Spencer Foundation's relentless commitment to supporting the mission of the Foundation Fighting Blindness to find treatments and cures for inherited retinal diseases," Benjamin Yerxa, PhD, chief executive officer, Foundation Fighting Blindness, said in a statement. "This level of investment drives the acceleration of the very best researchers in the retinal field."

According to the foundation, it will develop the Diana Davis Spencer Foundation Career Development Award to provide financial support and protected time to conduct clinical research to individuals with MD or MD/PhD degrees. This contribution will facilitate advances in laboratory and clinical research and ultimately lead to a clinical research career in the field of retinal diseases. Research projects and clinical training activities will focus on inherited retinal degenerative diseases.

"We're thrilled to continue our longstanding support for the Foundation Fighting Blindness," Abby Moffat, president and CEO of the Diana Davis Spencer Foundation, said in a statement. "We are proud of their half-century commitment as leaders in retinal research and look forward to the day these diseases are eradicated

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
© 2025 MJH Life Sciences

All rights reserved.